JAGX

Jaguar Health, Inc. is a commercial stage pharmaceuticals company. The Company is developing prescription medicines sustainably derived from plants from rainforest areas for people and animals with gastrointestinal distress, specifically associated with overactive bowel, which includes symptoms such as chronic debilitating diarrhea, urgency, bowel incontinence, and cramping pain. Its marketed drug Mytesi, (crofelemer 125 mg delayed-release tablets), is a first-in-class oral botanical drug product approved by the FDA for the symptomatic relief of noninfectious diarrhea in adults with HIV/AIDS on antiretroviral therapy. Its Canalevia-CA1, crofelemer delayed-release tablets drug, is an oral plant-based prescription product that is FDA conditionally approved to treat chemotherapy-induced diarrhea in dogs. It has an exclusive distribution agreement for the sale of Gelclair. It is developing a pipeline of prescription drug product candidates to address unmet needs in gastrointestinal health.

Wall Street analysts forecast JAGX stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for JAGX is  USD with a low forecast of USD and a high forecast of USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

Jaguar Health Inc revenue for the last quarter amounts to 3.08M USD, decreased -0.80 % YoY.

Jaguar Health Inc. EPS for the last quarter amounts to -6.28 USD, decreased -76.11 % YoY.

Jaguar Health Inc (JAGX) has 49 emplpoyees as of December 16 2025.

Today JAGX has the market capitalization of 4.45M USD.